Razelle Kurzrock
Experienced in Adrenocortical Carcinoma

Dr. Razelle Kurzrock

Hematology Oncology | Hematology | Oncology
9200 W Wisconsin Ave, 
Milwaukee, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
42 Years of Experience
Experienced in Adrenocortical Carcinoma
9200 W Wisconsin Ave, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Razelle Kurzrock is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Kurzrock has been practicing medicine for over 42 years and is rated as an Experienced provider by MediFind in the treatment of Adrenocortical Carcinoma. Her top areas of expertise are Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, Adult Soft Tissue Sarcoma, and Tissue Biopsy. Dr. Kurzrock is currently accepting new patients.

Her clinical research consists of co-authoring 734 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Adrenocortical Carcinoma.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Children's Community Health
  • EPO
  • PPO
Network Health
  • HMO

Locations

9200 W Wisconsin Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)
UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)
Enrollment Status: Recruiting
Publish Date: October 26, 2024
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: August 21, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: November 22, 2024
Intervention Type: Biological
Study Drug: Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
Study Phase: Phase 1
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling
Enrollment Status: Withdrawn
Publish Date: August 02, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway
A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway
Enrollment Status: Withdrawn
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

734 Total Publications

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).
Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).
Journal: JCO oncology advances
Published: December 08, 2025
Similar Doctors
Advanced in Adrenocortical Carcinoma
Dr. Alexandria T. Phan
Oncology | Hematology Oncology | Hematology
Advanced in Adrenocortical Carcinoma
Dr. Alexandria T. Phan
Oncology | Hematology Oncology | Hematology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (0.2 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexandria Phan is an Oncologist and a Hematologist Oncology provider in Milwaukee, Wisconsin. Dr. Phan is rated as a Distinguished provider by MediFind in the treatment of Adrenocortical Carcinoma. Her top areas of expertise are Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreatic Cancer, and Adrenocortical Carcinoma. Dr. Phan is currently accepting new patients.

Advanced in Adrenocortical Carcinoma
Dr. Paul S. Ritch
Oncology | Hematology
Advanced in Adrenocortical Carcinoma
Dr. Paul S. Ritch
Oncology | Hematology
9200 W Wisconsin Ave, Division Of Neoplastic Diseases, 
Milwaukee, WI 
 (0.1 miles away)
414-805-6800
Languages Spoken:
English
See accepted insurances

Paul Ritch is an Oncologist and a Hematologist in Milwaukee, Wisconsin. Dr. Ritch is rated as a Distinguished provider by MediFind in the treatment of Adrenocortical Carcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatectomy.

Experienced in Adrenocortical Carcinoma
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology
Experienced in Adrenocortical Carcinoma
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology

City Of Hope Medical Group Of Illinois PLLC

2520 Elisha Ave, 
Zion, IL 
 (42.1 miles away)
847-872-4561
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients

Walter Stadler is a Hematologist Oncology specialist and a Hematologist in Zion, Illinois. Dr. Stadler is rated as an Elite provider by MediFind in the treatment of Adrenocortical Carcinoma. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Orchiectomy, and Nephrectomy. Dr. Stadler is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kurzrock's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 28 Advanced Conditions
View All 57 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile